The mortality rate during the first month of infection for patients with advanced-stage hepatocellular carcinoma rose to 20.7%.
Researchers at the Hospital Clínic-IDIBAPS and the University of Barcelona have published a review article in the journal Nature Cancer in which they1
A multi-centre study, in which the Clínic-IDIBAPS participated, identified, in nearly 2,500 transplant patients, the main risk factors for the develo1
Immunotherapy has revolutionized the treatment of hepatocellular carcinoma. Researchers from the Hospital Clínic-IDIBAPS have published a review in t1
The inhibition of this molecule, in addition to reducing the predisposition towards developing the disease, also reduces the alteration of the microb1
Interview with Dr Maria Reig, head of the Hepatic Oncology Unit
Researchers at IDIBAPS have led a study, published in the journal Gastroenterology, in which they analyzed the clinical trials published in the past1
IDIBAPS researchers have drafted a molecular map of the most common type of liver cancer, hepatocellular carcinoma, when the origin is fatty liver di1
An article published in the journal Nature suggests that immunotherapy is effective in patients with HCC of viral origin but does not increase surviv1
Clínic-IDIBAPS researchers have coordinated two review articles on hepatocellular carcinoma (HCC), the most common type of liver cancer, in which the1
